KITE - Kite Pharma Stock Price, News & Analysis

$179.79 0.00 (0.00 %)
(As of 11/23/2017 04:00 PM ET)
Previous Close$179.79
Today's RangeN/A
52-Week Range$39.82 - $179.99
VolumeN/A
Average Volume1.65 million shs
Market Capitalization$10.28 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Kite Pharma (NASDAQ:KITE)

Kite Pharma logoKite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:KITE
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio9.01%
Quick Ratio9.01%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($6.90)
Net IncomeN/A
Net Margins-1,092.54%
Return on Equity-59.15%
Return on Assets-48.12%

Miscellaneous

Employees447
Outstanding Shares57,370,000

Frequently Asked Questions for Kite Pharma (NASDAQ:KITE)

What is Kite Pharma's stock symbol?

Kite Pharma trades on the NASDAQ under the ticker symbol "KITE."

How were Kite Pharma's earnings last quarter?

Kite Pharma, Inc. (NASDAQ:KITE) released its earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) EPS for the quarter, topping analysts' consensus estimates of ($1.75) by $0.05. The biopharmaceutical company had revenue of $4.90 million for the quarter, compared to the consensus estimate of $5.74 million. Kite Pharma had a negative return on equity of 59.15% and a negative net margin of 1,092.54%. Kite Pharma's quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.54) EPS. View Kite Pharma's Earnings History.

Where is Kite Pharma's stock going? Where will Kite Pharma's stock price be in 2017?

17 equities research analysts have issued twelve-month price targets for Kite Pharma's stock. Their forecasts range from $54.00 to $135.00. On average, they anticipate Kite Pharma's stock price to reach $93.20 in the next year. View Analyst Ratings for Kite Pharma.

What are Wall Street analysts saying about Kite Pharma stock?

Here are some recent quotes from research analysts about Kite Pharma stock:

  • 1. Cowen and Company analysts commented, "Competitor Novartis is scheduled to present pivotal data from CTL019’s JULIET trial in." (6/7/2017)
  • 2. Jefferies Group LLC analysts commented, "The NHS published a mock technology appraisal analysis to assess the value of CAR T therapy and determine a value-based price. The study was conducted for young ALL and determined a price of ??530K ($649K) was justified. We view this price as an upper limit for Axi-Cel pricing, and raise our Axi-Cel price estimate to $300K (prev' $200K). We also decreased WACC to 13% (prev 15%) which was offset by moderating share to drive our new PT of $101." (3/16/2017)
  • 3. Canaccord Genuity analysts commented, "The Kochenderfer study for CAR-19 published in the Journal of Clinical Oncology showed 12 months' median duration of complete response, suggesting positive read-through generally speaking for ZUMA-1. Importantly, 11 of 12 complete responses (CRs) are still ongoing, suggesting the potential for very long-term remission. We believe the CAR-19 data suggest that KTE-C19 is a favorable option for NHL patients with few, if any, other treatment options, which may provide long-term potentially curative benefit." (3/15/2017)
  • 4. Wedbush analysts commented, "KITE is poised to complete submission of the first BLA for a CAR-T therapy, but we believe slow adoption of the new treatment modality may blunt its first mover advantage, as CAR-T competition matures and treatment strategies evolve to address safety and efficacy challenges." (2/1/2017)

Who are some of Kite Pharma's key competitors?

Who are Kite Pharma's key executives?

Kite Pharma's management team includes the folowing people:

  • Arie S. Belldegrun, Executive Chairman of the Board, President, Chief Executive Officer, Founder
  • Paul L. Jenkinson, Chief Financial Officer
  • Cynthia M. Butitta, Chief Operating Officer
  • David Chang M.D. Ph.D., Executive Vice President - Research and Development, Chief Medical Officer
  • Helen S. Kim, Executive Vice President - Business Development
  • Timothy L. Moore, Executive Vice President - Technical Operations
  • Christine Cassiano, Senior Vice President - Corporate Communications and Investor Relations
  • , Bio & Compensation - 
  • Jian Irish Ph.D., Senior Vice President - Supply Chain
  • , Bio & Compensation - 
  • Jeffrey Wiezorek M.D., Senior Vice President - Clinical Development
  • Shawn Cline Tomasello, Chief Commercial Officer

Who owns Kite Pharma stock?

Kite Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Cowen Inc. (7.32%), Cheyne Capital Management UK LLP (1.73%), Omni Partners LLP (1.15%), Gabelli Funds LLC (1.09%), OxFORD Asset Management LLP (0.78%) and First Trust Advisors LP (0.73%). Company insiders that own Kite Pharma stock include Arie Belldegrun, Cynthia M Butitta, David Bonderman, David D Chang, Farah Champsi, Helen Susan Kim, Jeffrey Wiezorek, Marc Better, Margo R Roberts, Owen N Witte, Paul L Jenkinson, Rizwana F Sproule, Roy Doumani, Shawn Tomasello, Steven B Ruchefsky and Timothy L Moore. View Institutional Ownership Trends for Kite Pharma.

Who sold Kite Pharma stock? Who is selling Kite Pharma stock?

Kite Pharma's stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Menora Mivtachim Holdings LTD., American Century Companies Inc., DSAM Partners London Ltd, California Public Employees Retirement System, TD Asset Management Inc., First Trust Advisors LP and Russell Investments Group Ltd.. Company insiders that have sold Kite Pharma company stock in the last year include Arie Belldegrun, Cynthia M Butitta, David D Chang, Farah Champsi, Helen Susan Kim, Jeffrey Wiezorek, Owen N Witte, Paul L Jenkinson, Roy Doumani, Shawn Tomasello, Steven B Ruchefsky and Timothy L Moore. View Insider Buying and Selling for Kite Pharma.

Who bought Kite Pharma stock? Who is buying Kite Pharma stock?

Kite Pharma's stock was purchased by a variety of institutional investors in the last quarter, including Cowen Inc., Cheyne Capital Management UK LLP, Omni Partners LLP, Gabelli Funds LLC, OxFORD Asset Management LLP, Alyeska Investment Group L.P., Pentwater Capital Management LP and Eagle Asset Management Inc.. Company insiders that have bought Kite Pharma stock in the last two years include Arie Belldegrun, David Bonderman and Paul L Jenkinson. View Insider Buying and Selling for Kite Pharma.

How do I buy Kite Pharma stock?

Shares of Kite Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kite Pharma's stock price today?

One share of Kite Pharma stock can currently be purchased for approximately $179.79.

How big of a company is Kite Pharma?

Kite Pharma has a market capitalization of $10.28 billion. Kite Pharma employs 447 workers across the globe.

How can I contact Kite Pharma?

Kite Pharma's mailing address is 2225 Colorado Ave, SANTA MONICA, CA 90404-3505, United States. The biopharmaceutical company can be reached via phone at +1-310-8249999.


MarketBeat Community Rating for Kite Pharma (KITE)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  599 (Vote Outperform)
Underperform Votes:  266 (Vote Underperform)
Total Votes:  865
MarketBeat's community ratings are surveys of what our community members think about Kite Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Kite Pharma (NASDAQ:KITE)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 10 Hold Ratings, 7 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.41)
Consensus Price Target: $93.20 (48.16% downside)

Consensus Price Target History for Kite Pharma (NASDAQ:KITE)

Price Target History for Kite Pharma (NASDAQ:KITE)

Analysts' Ratings History for Kite Pharma (NASDAQ:KITE)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/29/2017WedbushUpgradeUnderperform -> NeutralLowView Rating Details
8/29/2017Canaccord GenuityDowngradeBuy -> HoldLowView Rating Details
8/28/2017GuggenheimDowngradeBuy -> Neutral$128.00LowView Rating Details
8/28/2017SunTrust Banks, Inc.DowngradeBuy -> HoldMediumView Rating Details
8/28/2017BTIG ResearchDowngradeBuy -> NeutralHighView Rating Details
8/10/2017Stifel NicolausReiterated RatingHold$74.00LowView Rating Details
8/9/2017Jefferies Group LLCReiterated RatingBuy$121.00 -> $135.00LowView Rating Details
7/13/2017Maxim GroupDowngradeBuy -> Hold$88.00LowView Rating Details
7/4/2017Roth CapitalReiterated RatingBuy$93.00MediumView Rating Details
7/4/2017Cowen and CompanyReiterated RatingOutperformMediumView Rating Details
5/30/2017FBR & CoReiterated RatingBuyLowView Rating Details
5/19/2017HC WainwrightReiterated RatingBuy$85.00MediumView Rating Details
5/15/2017Raymond James Financial, Inc.DowngradeOutperform -> Mkt PerformN/AView Rating Details
5/9/2017Goldman Sachs Group, Inc. (The)Boost Price TargetBuy$85.00 -> $89.00HighView Rating Details
3/13/2017Standpoint ResearchDowngradeBuy -> Hold$85.00LowView Rating Details
3/6/2017Royal Bank Of CanadaBoost Price TargetOutperform$85.00 -> $95.00N/AView Rating Details
3/2/2017Citigroup Inc.DowngradeBuy -> Neutral$62.00 -> $87.00N/AView Rating Details
2/22/2017Wells Fargo & CompanyInitiated CoverageMarket Perform -> Market PerformN/AView Rating Details
9/27/2016Barclays PLCBoost Price TargetEqual Weight$60.00 -> $65.00N/AView Rating Details
8/9/2016MizuhoSet Price TargetBuy$80.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Kite Pharma (NASDAQ:KITE)

Earnings by Quarter for Kite Pharma (NASDAQ:KITE)

Earnings History by Quarter for Kite Pharma (NASDAQ KITE)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($1.97)($1.94)$9.59 million$10.10 millionViewListenView Earnings Details
5/8/2017Q1 2017($1.68)($1.74)$8.85 million$9.80 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.75)($1.70)$5.74 million$4.90 millionViewListenView Earnings Details
11/9/2016Q316($1.68)($1.49)$4.94 million$7.34 millionViewListenView Earnings Details
8/8/2016Q216($1.21)($0.91)$4.86 million$4.80 millionViewN/AView Earnings Details
5/9/2016Q116($1.08)($0.90)$4.61 million$5.10 millionViewN/AView Earnings Details
2/29/2016Q4($0.71)($0.85)$4.54 million$4.89 millionViewListenView Earnings Details
11/12/2015Q315($0.64)($0.63)$4.06 million$5.10 millionViewListenView Earnings Details
8/10/2015Q215($0.41)($0.48)$2.51 million$4.40 millionViewListenView Earnings Details
5/15/2015Q115$1.16($0.36)$19.70 million$2.90 millionViewN/AView Earnings Details
3/26/2015Q414($0.16)($0.33)ViewN/AView Earnings Details
11/14/2014Q314($0.23)($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kite Pharma (NASDAQ:KITE)
2017 EPS Consensus Estimate: ($7.72)
2018 EPS Consensus Estimate: ($7.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175($1.79)($1.36)($1.60)
Q2 20175($1.93)($1.53)($1.76)
Q3 20175($2.26)($1.91)($2.09)
Q4 20175($2.49)($1.99)($2.27)
Q1 20182($2.26)($1.89)($2.08)
Q2 20182($2.26)($1.74)($2.00)
Q3 20182($2.21)($1.81)($2.01)
Q4 20182($1.96)($1.80)($1.88)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Kite Pharma (NASDAQ:KITE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Kite Pharma (NASDAQ KITE)

Insider Ownership Percentage: 14.00%
Institutional Ownership Percentage: 87.72%
Insider Trades by Quarter for Kite Pharma (NASDAQ:KITE)
Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)

Insider Trades by Quarter for Kite Pharma (NASDAQ KITE)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/25/2017Arie BelldegrunChairmanSell26,347$179.66$4,733,502.02View SEC Filing  
9/25/2017Cynthia M ButittaCOOSell4,228$179.66$759,602.48View SEC Filing  
9/25/2017David D. ChangEVPSell7,927$179.66$1,424,164.82View SEC Filing  
9/25/2017Jeffrey WiezorekSVPSell5,283$179.66$949,143.78View SEC Filing  
9/25/2017Paul L. JenkinsonCFOSell948$179.66$170,317.68View SEC Filing  
9/25/2017Shawn TomaselloInsiderSell4,203$179.66$755,110.98View SEC Filing  
8/10/2017Cynthia M ButittaCOOSell15,000$120.72$1,810,800.00View SEC Filing  
8/10/2017Helen Susan KimEVPSell6,251$120.09$750,682.59View SEC Filing  
8/8/2017Helen Susan KimEVPSell79,949$119.56$9,558,702.44View SEC Filing  
8/3/2017Timothy L MooreEVPSell6,000$110.06$660,360.00View SEC Filing  
8/1/2017Timothy L MooreEVPSell12,000$107.69$1,292,280.00View SEC Filing  
7/31/2017Helen Susan KimEVPSell26,649$109.28$2,912,202.72View SEC Filing  
7/10/2017Cynthia M ButittaCOOSell15,000$103.09$1,546,350.00View SEC Filing  
7/3/2017Jeffrey WiezorekSVPSell10,000$104.32$1,043,200.00View SEC Filing  
6/26/2017Owen N WitteDirectorSell25,000$100.30$2,507,500.00View SEC Filing  
6/23/2017Cynthia M ButittaCOOSell5,000$100.81$504,050.00View SEC Filing  
6/16/2017Farah ChampsiDirectorSell20,450$89.79$1,836,205.50View SEC Filing  
6/14/2017Steven B RuchefskyDirectorSell20,000$89.48$1,789,600.00View SEC Filing  
6/9/2017Cynthia M ButittaCOOSell10,000$88.55$885,500.00View SEC Filing  
6/8/2017Roy DoumaniDirectorSell15,000$84.48$1,267,200.00View SEC Filing  
5/10/2017Paul L. JenkinsonCFOBuy3,450$72.59$250,435.50View SEC Filing  
5/9/2017Arie BelldegrunChairmanBuy17,000$68.57$1,165,690.00View SEC Filing  
5/9/2017David BondermanDirectorBuy50,000$68.94$3,447,000.00View SEC Filing  
5/1/2017David D ChangEVPSell20,000$82.09$1,641,800.00View SEC Filing  
4/28/2017Farah ChampsiDirectorSell19,168$82.75$1,586,152.00View SEC Filing  
4/26/2017Farah ChampsiDirectorSell123,913$82.67$10,243,887.71View SEC Filing  
4/25/2017Cynthia M ButittaCOOSell15,000$81.85$1,227,750.00View SEC Filing  
4/25/2017Farah ChampsiDirectorSell46,783$82.80$3,873,632.40View SEC Filing  
4/24/2017Farah ChampsiDirectorSell25,818$82.34$2,125,854.12View SEC Filing  
4/17/2017Farah ChampsiDirectorSell115,376$82.42$9,509,289.92View SEC Filing  
4/3/2017Cynthia M ButittaCOOSell5,000$81.96$409,800.00View SEC Filing  
4/3/2017Helen Susan KimEVPSell2,400$81.80$196,320.00View SEC Filing  
3/27/2017Cynthia M ButittaCOOSell10,000$77.67$776,700.00View SEC Filing  
3/15/2017Timothy L MooreEVPSell7,511$83.31$625,741.41View SEC Filing  
3/9/2017Cynthia M ButittaCOOSell21,118$80.78$1,705,912.04View SEC Filing  
3/1/2017Cynthia M ButittaCOOSell38,882$73.46$2,856,271.72View SEC Filing  
3/1/2017Helen Susan KimEVPSell50,300$67.78$3,409,334.00View SEC Filing  
3/1/2017Jeffrey WiezorekSVPSell18,000$75.01$1,350,180.00View SEC Filing  
3/1/2017Roy DoumaniDirectorSell18,800$74.46$1,399,848.00View SEC Filing  
2/27/2017Cynthia M ButittaCOOSell10,000$54.42$544,200.00View SEC Filing  
1/31/2017Cynthia M ButittaCOOSell10,000$50.56$505,600.00View SEC Filing  
1/6/2017Cynthia M ButittaCOOSell10,000$50.13$501,300.00View SEC Filing  
1/6/2017Jeffrey WiezorekSVPSell1,500$50.00$75,000.00View SEC Filing  
12/20/2016Arie BelldegrunChairmanSell3,493$50.86$177,653.98View SEC Filing  
12/20/2016Cynthia M ButittaCOOSell2,482$50.86$126,234.52View SEC Filing  
12/20/2016David D. ChangEVPSell1,788$50.86$90,937.68View SEC Filing  
12/20/2016Jeffrey WiezorekSVPSell716$50.86$36,415.76View SEC Filing  
12/20/2016Shawn TomaselloInsiderSell4,901$50.86$249,264.86View SEC Filing  
12/1/2016Jeffrey WiezorekSVPSell1,500$50.76$76,140.00View SEC Filing  
11/25/2016Cynthia M ButittaCOOSell10,000$50.40$504,000.00View SEC Filing  
10/3/2016Jeffrey WiezorekSVPSell1,500$54.81$82,215.00View SEC Filing  
9/26/2016Cynthia M ButittaCOOSell10,000$54.13$541,300.00View SEC Filing  
9/1/2016Jeffrey WiezorekSVPSell1,500$58.24$87,360.00View SEC Filing  
8/25/2016Cynthia M. ButittaCOOSell10,000$58.28$582,800.00View SEC Filing  
8/15/2016Helen Susan KimEVPSell35,900$60.27$2,163,693.00View SEC Filing  
8/1/2016Jeffrey WiezorekSVPSell1,500$56.90$85,350.00View SEC Filing  
7/25/2016Cynthia M ButittaCOOSell10,000$50.94$509,400.00View SEC Filing  
7/1/2016Jeffrey WiezorekSVPSell1,500$50.00$75,000.00View SEC Filing  
6/27/2016Cynthia M ButittaCOOSell20,000$50.71$1,014,200.00View SEC Filing  
6/6/2016Roy DoumaniDirectorSell10,000$57.91$579,100.00View SEC Filing  
6/1/2016Jeffrey WiezorekSVPSell3,000$50.65$151,950.00View SEC Filing  
4/4/2016Cynthia M ButittaCFOSell10,000$50.00$500,000.00View SEC Filing  
3/15/2016Jeffrey WiezorekSVPSell9,000$44.88$403,920.00View SEC Filing  
3/15/2016Margo R RobertsInsiderSell8,506$45.23$384,726.38View SEC Filing  
3/15/2016Rizwana F SprouleVPSell8,500$45.27$384,795.00View SEC Filing  
3/1/2016Cynthia M. ButittaCFOSell10,000$50.03$500,300.00View SEC Filing  
2/17/2016Margo R. RobertsinsiderSell9,632$45.06$434,017.92View SEC Filing  
2/17/2016Rizwana F. SprouleVPSell9,567$45.08$431,280.36View SEC Filing  
2/12/2016Margo R. RobertsinsiderSell18,750$64.16$1,203,000.00View SEC Filing  
2/2/2016Cynthia M. ButittaCFOSell1,900$50.13$95,247.00View SEC Filing  
2/1/2016Marc BetterVPSell9,000$47.34$426,060.00View SEC Filing  
1/27/2016Cynthia M. ButittaCFOSell8,100$51.62$418,122.00View SEC Filing  
1/19/2016Rizwana F. SprouleVPSell9,567$55.49$530,872.83View SEC Filing  
1/15/2016Jeffrey WiezorekSVPSell9,000$55.26$497,340.00View SEC Filing  
1/15/2016Margo R. RobertsinsiderSell6,145$55.22$339,326.90View SEC Filing  
1/4/2016Marc BetterVPSell9,000$61.53$553,770.00View SEC Filing  
12/28/2015Cynthia M. ButittaCFOSell10,000$61.56$615,600.00View SEC Filing  
11/27/2015Cynthia M. ButittaCFOSell15,000$86.45$1,296,750.00View SEC Filing  
11/16/2015Jeffrey WiezorekSVPSell9,000$78.08$702,720.00View SEC Filing  
11/16/2015Margo R. RobertsinsiderSell6,145$78.16$480,293.20View SEC Filing  
11/16/2015Rizwana F. SprouleVPSell9,567$78.13$747,469.71View SEC Filing  
11/2/2015David D. ChangEVPSell7,700$71.08$547,316.00View SEC Filing  
11/2/2015Marc BetterVPSell9,000$71.07$639,630.00View SEC Filing  
10/27/2015Cynthia M. ButittaCFOSell10,000$69.91$699,100.00View SEC Filing  
10/15/2015Jeffrey WiezorekSVPSell9,000$62.59$563,310.00View SEC Filing  
10/15/2015Margo R. RobertsinsiderSell6,145$62.57$384,492.65View SEC Filing  
10/15/2015Rizwana F. SprouleVPSell9,567$62.58$598,702.86View SEC Filing  
10/1/2015David D. ChangEVPSell7,700$55.11$424,347.00View SEC Filing  
10/1/2015Marc BetterVPSell9,000$54.81$493,290.00View SEC Filing  
9/28/2015Cynthia M. ButittaCFOSell10,000$55.87$558,700.00View SEC Filing  
9/15/2015Margo R. RobertsinsiderSell6,145$64.33$395,307.85View SEC Filing  
9/15/2015Rizwana F. SprouleVPSell9,567$64.36$615,732.12View SEC Filing  
9/8/2015David D. ChangEVPSell7,700$55.00$423,500.00View SEC Filing  
9/1/2015Marc BetterVPSell9,000$51.81$466,290.00View SEC Filing  
8/27/2015Cynthia M. ButittaCFOSell10,000$53.62$536,200.00View SEC Filing  
8/17/2015Jeffrey WiezorekVPSell9,000$60.87$547,830.00View SEC Filing  
8/17/2015Margo R RobertsInsiderSell6,145$60.90$374,230.50View SEC Filing  
7/1/2015David D ChangEVPSell7,700$61.92$476,784.00View SEC Filing  
7/1/2015Marc BetterVPSell9,000$61.90$557,100.00View SEC Filing  
6/29/2015Cynthia M ButittaCFOSell10,000$59.65$596,500.00View SEC Filing  
6/25/2015Jeffrey WiezorekVPBuy4,000$17.00$68,000.00View SEC Filing  
6/15/2015David D ChangEVPSell7,700$56.98$438,746.00View SEC Filing  
6/15/2015Margo R RobertsInsiderSell8,625$56.99$491,538.75View SEC Filing  
6/15/2015Rizwana F SprouleVPSell9,567$56.98$545,127.66View SEC Filing  
6/2/2015Ran NussbaumDirectorSell305,434$55.35$16,905,771.90View SEC Filing  
6/1/2015Marc BetterVPSell9,000$54.60$491,400.00View SEC Filing  
6/1/2015Ran NussbaumDirectorSell80,760$55.34$4,469,258.40View SEC Filing  
4/27/2015Cynthia M ButittaCFOSell10,000$59.76$597,600.00View SEC Filing  
3/30/2015Ran NussbaumDirectorSell193,730$60.45$11,710,978.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Kite Pharma (NASDAQ KITE)

Source:
DateHeadline
7 Life Science Stocks to Buy Today - Yahoo News7 Life Science Stocks to Buy Today - Yahoo News
finance.yahoo.com - November 15 at 3:51 AM
Kite Pharma Inc (KITE) Given Consensus Recommendation of "Hold" by AnalystsKite Pharma Inc (KITE) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 12 at 9:54 AM
UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors - GlobeNewswire (press release)UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors - GlobeNewswire (press release)
globenewswire.com - November 4 at 4:08 AM
Juno touts latest cancer drug results after rivals win FDA approval - Puget Sound Business Journal (Seattle)Juno touts latest cancer drug results after rivals win FDA approval - Puget Sound Business Journal (Seattle)
www.bizjournals.com - November 2 at 4:20 AM
Kite Pharma Inc (KITE) to Release Quarterly Earnings on TuesdayKite Pharma Inc (KITE) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:36 AM
UPDATE 2-Gilead weak hepatitis C sales outlook sends shares lowerUPDATE 2-Gilead weak hepatitis C sales outlook sends shares lower
www.cnbc.com - October 26 at 9:28 PM
Gilead revenue falls 13%, worst yet to comeGilead revenue falls 13%, worst yet to come
www.marketwatch.com - October 26 at 9:28 PM
BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta™ (Axicabtagene Ciloleucel) CAR T-Cell ... - PR Newswire (press release)BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta™ (Axicabtagene Ciloleucel) CAR T-Cell ... - PR Newswire (press release)
www.prnewswire.com - October 20 at 2:37 AM
The Math Behind the Gileads Recent Merger - Seeking AlphaThe Math Behind the Gilead's Recent Merger - Seeking Alpha
seekingalpha.com - October 18 at 3:40 PM
Kite Pharma, Inc. (KITE) Receives Consensus Recommendation of "Hold" from BrokeragesKite Pharma, Inc. (KITE) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 18 at 12:50 PM
Q3 Roundup: Top 5 Performing KnivesQ3 Roundup: Top 5 Performing Knives
seekingalpha.com - October 16 at 5:09 AM
Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma BuyGilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy
investorplace.com - October 13 at 10:34 AM
Immunotherapy Treatments for Cancer Gain MomentumImmunotherapy Treatments for Cancer Gain Momentum
www.msn.com - October 13 at 6:14 AM
Vertex Pharmaceuticals: Excellence In Cystic Fibrosis, Strong Potential AheadVertex Pharmaceuticals: Excellence In Cystic Fibrosis, Strong Potential Ahead
seekingalpha.com - October 10 at 7:42 PM
Form 4 Kite Pharma, Inc. For: Oct 03 Filed by: Peacock Jonathan M - StreetInsider.comForm 4 Kite Pharma, Inc. For: Oct 03 Filed by: Peacock Jonathan M - StreetInsider.com
www.streetinsider.com - October 7 at 1:36 AM
Gilead Sciences Completes Acquisition of Kite Pharma, Inc. - Business Wire (press release)Gilead Sciences Completes Acquisition of Kite Pharma, Inc. - Business Wire (press release)
www.businesswire.com - October 5 at 6:33 AM
Gilead Sciences: We Dont Think That His Departure Is a Red HerringGilead Sciences: 'We Don't Think That His Departure Is a Red Herring'
finance.yahoo.com - October 2 at 12:36 PM
Better Buy: Gilead Sciences, Inc. vs. PfizerBetter Buy: Gilead Sciences, Inc. vs. Pfizer
finance.yahoo.com - October 2 at 12:36 PM
Here's Why Bluebird Bio (BLUE) Stock Is Falling TodayHere's Why Bluebird Bio (BLUE) Stock Is Falling Today
finance.yahoo.com - October 2 at 12:36 PM
 Brokerages Anticipate Kite Pharma, Inc. (KITE) Will Announce Earnings of -$2.13 Per Share Brokerages Anticipate Kite Pharma, Inc. (KITE) Will Announce Earnings of -$2.13 Per Share
www.americanbankingnews.com - October 2 at 10:26 AM
Exclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sourcesExclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sources
www.reuters.com - September 30 at 12:13 AM
Why Biotech and Tech Will Push Stocks Higher In 4QWhy Biotech and Tech Will Push Stocks Higher In 4Q
www.investopedia.com - September 29 at 2:07 PM
Daily Technical Summary Reports on Biotech Stocks -- Gilead Sciences, Kite ...Daily Technical Summary Reports on Biotech Stocks -- Gilead Sciences, Kite ...
www.prnewswire.com - September 29 at 2:07 PM
Form 4 Kite Pharma, Inc. For: Sep 25 Filed by: Tomasello ShawnForm 4 Kite Pharma, Inc. For: Sep 25 Filed by: Tomasello Shawn
www.streetinsider.com - September 28 at 10:12 AM
Insider Selling: Kite Pharma, Inc. (KITE) CFO Sells 948 Shares of StockInsider Selling: Kite Pharma, Inc. (KITE) CFO Sells 948 Shares of Stock
www.americanbankingnews.com - September 27 at 10:32 PM
Kite Pharma, Inc. (KITE) Insider Shawn Tomasello Sells 4,203 SharesKite Pharma, Inc. (KITE) Insider Shawn Tomasello Sells 4,203 Shares
www.americanbankingnews.com - September 27 at 10:30 PM
Insider Selling: Kite Pharma, Inc. (KITE) EVP Sells 7,511 Shares of StockInsider Selling: Kite Pharma, Inc. (KITE) EVP Sells 7,511 Shares of Stock
www.americanbankingnews.com - September 27 at 10:30 PM
Cynthia M. Butitta Sells 4,228 Shares of Kite Pharma, Inc. (KITE) StockCynthia M. Butitta Sells 4,228 Shares of Kite Pharma, Inc. (KITE) Stock
www.americanbankingnews.com - September 27 at 10:30 PM
Insider Selling: Kite Pharma, Inc. (KITE) Chairman Sells 26,347 Shares of StockInsider Selling: Kite Pharma, Inc. (KITE) Chairman Sells 26,347 Shares of Stock
www.americanbankingnews.com - September 27 at 10:30 PM
Kite Pharma, Inc. (KITE) EVP David D. Chang Sells 7,927 SharesKite Pharma, Inc. (KITE) EVP David D. Chang Sells 7,927 Shares
www.americanbankingnews.com - September 27 at 10:30 PM
Kite Pharma, Inc. (KITE) SVP Jeffrey Wiezorek Sells 5,283 SharesKite Pharma, Inc. (KITE) SVP Jeffrey Wiezorek Sells 5,283 Shares
www.americanbankingnews.com - September 27 at 10:30 PM
Kite Pharma Triples So Far in 2017: Whats Driving the Rally?Kite Pharma Triples So Far in 2017: What's Driving the Rally?
www.nasdaq.com - September 27 at 6:09 PM
Wildcat Capital: Drew Tarlow, Len Potter, Family Office Of The YearWildcat Capital: Drew Tarlow, Len Potter, Family Office Of The Year
finance.yahoo.com - September 25 at 4:58 PM
Now That Gileads Bought Kite, Are Doctors Ready To Use CAR T Cancer Therapy?Now That Gilead's Bought Kite, Are Doctors Ready To Use CAR T Cancer Therapy?
finance.yahoo.com - September 25 at 4:58 PM
[$$] Getting Ready for Gileads CAR-T[$$] Getting Ready for Gilead's CAR-T
finance.yahoo.com - September 25 at 4:58 PM
Tempur Sealy Promotes Bhaskar Rao To Chief Financial OfficerTempur Sealy Promotes Bhaskar Rao To Chief Financial Officer
www.thestreet.com - September 25 at 9:03 AM
Kite Pharma, Inc. (KITE) Receives Average Recommendation of "Hold" from BrokeragesKite Pharma, Inc. (KITE) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 23 at 10:48 AM
Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU ApprovalPfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval
www.nasdaq.com - September 22 at 11:54 AM
Gilead Sciences Kite Pharma Deal Has Already Paid for Itself -- for Investors - Motley FoolGilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors - Motley Fool
www.fool.com - September 21 at 3:49 PM
Why Gilead Sciences Is Flying High With KiteWhy Gilead Sciences Is Flying High With Kite
finance.yahoo.com - September 21 at 3:48 PM
Why Drug Stocks Will Outperform the S&P and DowWhy Drug Stocks Will Outperform the S&P and Dow
www.investopedia.com - September 19 at 11:43 PM
Short Interest in Kite Pharma, Inc. (KITE) Drops By 32.7%Short Interest in Kite Pharma, Inc. (KITE) Drops By 32.7%
www.americanbankingnews.com - September 15 at 1:28 AM
Gilead Sciences CEO and oncology chief take on direct questions about why buying Kite was the right move. - Motley FoolGilead Sciences CEO and oncology chief take on direct questions about why buying Kite was the right move. - Motley Fool
www.fool.com - September 12 at 2:41 AM
Implied Volatility Surging for Kite Pharma (KITE) Stock Options - NasdaqImplied Volatility Surging for Kite Pharma (KITE) Stock Options - Nasdaq
www.nasdaq.com - September 12 at 2:41 AM
Cryoport Selected to Support the Potential Commercial Launch of Kite Pharmas CAR-T Therapy Axicabtagene CiloleucelCryoport Selected to Support the Potential Commercial Launch of Kite Pharma's CAR-T Therapy Axicabtagene Ciloleucel
www.prnewswire.com - September 5 at 5:04 PM
Biotech Stocks Back in Favor: Will the Rally Continue?Biotech Stocks Back in Favor: Will the Rally Continue?
finance.yahoo.com - September 5 at 5:03 PM
Gilead Sciences Couldn't Have Timed its Splash Into CAR-T BetterGilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
finance.yahoo.com - September 5 at 5:03 PM
Why Its Useful To Know A Companys Competitors When TradingWhy It's Useful To Know A Company's Competitors When Trading
finance.yahoo.com - September 5 at 5:03 PM
Gileads Plans To Acquire Kite Pharma Just Got Big-Time Validation From Novartis - Seeking AlphaGilead's Plans To Acquire Kite Pharma Just Got Big-Time Validation From Novartis - Seeking Alpha
seekingalpha.com - September 3 at 12:10 AM
Kite Pharma Inc (KITE): FDA Approval of Kymriah Is Good News for the Future of Axi-cel - Yahoo FinanceKite Pharma Inc (KITE): FDA Approval of Kymriah Is Good News for the Future of Axi-cel - Yahoo Finance
finance.yahoo.com - September 2 at 2:56 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Kite Pharma (NASDAQ KITE) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.